Skip to main content

Pharvaris, N.V (PHVS)

NASDAQ: PHVS · IEX Real-Time Price · USD
15.25 0.45 (3.04%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap505.21M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out33.09M
EPS (ttm)-4.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,784
Open14.52
Previous Close14.80
Day's Range14.52 - 15.98
52-Week Range13.14 - 42.86
Betan/a
AnalystsBuy
Price Target42.91 (+181.4%)
Est. Earnings DateOct 29, 2021

About PHVS

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees17
Stock ExchangeNASDAQ
Ticker SymbolPHVS
Full Company Profile

Financial Performance

Financial numbers in millions EuroFinancial Statements

Analyst Forecast

According to 4 analysts, the average rating for Pharvaris stock is "Buy." The 12-month stock price forecast is 42.91, which is an increase of 181.38% from the latest price.

Price Target
$42.91
(181.38% upside)
Analyst Consensus: Buy

News

Pharvaris to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists ...

1 month ago - GlobeNewsWire

Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

2 months ago - GlobeNewsWire

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the...

Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE Multiple doses of PHA121 were well-tolerated and showed a favorable pharmaco...

3 months ago - GlobeNewsWire

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

3 months ago - GlobeNewsWire

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

4 months ago - GlobeNewsWire

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of H...

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

4 months ago - GlobeNewsWire

Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights

ZUG, Switzerland, May 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists fo...

4 months ago - GlobeNewsWire

Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...

5 months ago - GlobeNewsWire

Pharvaris to Participate in BioCapital Europe

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...

7 months ago - GlobeNewsWire

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the t...

7 months ago - GlobeNewsWire

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI ...

Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers

8 months ago - GlobeNewsWire

Pharvaris Announces Closing of Initial Public Offering

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...

8 months ago - GlobeNewsWire

Pharvaris Announces Pricing of Upsized Initial Public Offering Nasdaq:PHVS

ZUG, Switzerland-- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery,...

8 months ago - GlobeNewswire

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatme...

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema.

8 months ago - Pipeline Review

Dutch rare disease biotech Pharvaris files for a $100 million US IPO

Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

9 months ago - NASDAQ

Pharvaris IPO Registration Document (S-1)

Pharvaris, N.V has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC